SCHEMBL5340608

SCHEMBL5340608

O=c1cc(O)c2cc3cccc(OCc4ccccc4)c3cc2o1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.50
NPC1 O15118 2/20 0.46
MAOA P21397 2/20 0.46
CASP3 P42574 1/20 0.46
RAB9A P51151 1/20 0.46
SENP8 Q96LD8 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SENP6 Q9GZR1 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
BCHE P06276 1/20 0.46
ACHE P22303 1/20 0.46
MRGPRX4 Q96LA9 1/20 0.45
MEN1 O00255 1/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA3 P07451 1/20 0.44
CA4 P22748 1/20 0.44
CA6 P23280 1/20 0.44
CA7 P43166 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7546749 0.80 BCHE (0.60) MAOBNPC1MAOACASP3RAB9A
SCHEMBL5337634 0.80 CTDSP1 (0.53) MAOATDP1MEN1CA12CA1
SCHEMBL5338193 0.80 MAOB (0.61) MAOBNPC1MAOACASP3RAB9A
SCHEMBL11168197 0.78 MRGPRX4 (0.54) MAOBTDP1MRGPRX4
SCHEMBL7549470 0.76 PKM (0.72) MAOBNPC1MAOACASP3RAB9A
SCHEMBL7549311 0.76 MAOB (0.72) MAOBNPC1MAOACASP3RAB9A
SCHEMBL5337919 0.76 CA12 (0.54) TDP1BCHEACHEMEN1CA12
SCHEMBL16274610 0.76 MAPT (0.55) MAOBNPC1RAB9ATDP1MRGPRX4
SCHEMBL11095625 0.75 HSD17B3 (0.63) MAOBNPC1MAOACASP3RAB9A
Methane SCHEMBL28950844 0.74 MAPT (0.53) MAOBNPC1RAB9ATDP1MRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7208518-B2 Substituted furochromene compounds of antiinflammatory action GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) 2007-04-24 US disclosed
US-20060148890-A1 Substituted furochromene compounds of antiinflammatory action PLIVA-LSTRAZIVACKI INSTITUT D.O.O. (HR) 2006-07-06 US disclosed
EP-1648901-A1 SUBSTITUTED FUROCHROMENE COMPOUNDS OF ANTIINFLAMMATORY ACTION PLIVA-ISTRAZIVACKI INSTITUT d.o.o. (HR) 2006-04-26 EP disclosed
WO-2005010006-A1 SUBSTITUTED FUROCHROMENE COMPOUNDS OF ANTIINFLAMMATORY ACTION PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148890-A1 Substituted furochromene compounds of antiinflammatory action LTC4S, CYP11B2, CYP11B1 MAOB 533/4885NPC1 2734/4885MAOA 547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.